Effectiveness and Safety Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory (R/R) Transformed Large B-Cell Lymphoma (tLBCL): Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
Isufi I, Crombie J, Frigault M, Andreadis C, Lin Y, Mirza A, Kim S, Bernasconi D, Toron F, Krimmel T, Roy D, Pasquini M, Ahmed S. Effectiveness and Safety Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory (R/R) Transformed Large B-Cell Lymphoma (tLBCL): Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Transplantation And Cellular Therapy 2025, 31: s215. DOI: 10.1016/j.jtct.2025.01.329.Peer-Reviewed Original ResearchImmune effector cell-associated neurotoxicity syndromeCytokine release syndromeDuration of responseLiso-celNonrelapse mortalityCR rateCenter for International Blood and Marrow Transplant Research (CIBMTR) registryMedian duration of responseCAR-T cell productsLarge B-cell lymphomaB-cell lymphomaClinically significant infectionsB-cell malignanciesT cell productionConsistent with clinical studiesCD19-directedExtranodal involvementLisocabtagene maraleucelNRM ratesProlonged cytopeniasR/R LBCLIndolent lymphomaData cutoffElevated LDHRadiation therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply